argenx SE
VYVGART
autoimmune inflammatory myopathies (AIM or myositis)
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for VYVGART in autoimmune inflammatory myopathies (AIM or myositis) are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Topline results expected for ocular MG (ADAPT OCULUS) in first quarter of 2026”